Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CPAP Treatment Adherence in Women with Obstructive Sleep Apnea.

Sleep disorders·2017
Same author

The CMA president responds to Monique Bégin's letter.

Canadian Medical Association journal·2010
Same author

Assessing the impact of pulmonary rehabilitation on functional status in COPD.

Thorax·2007
Same author

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts.

The European respiratory journal·2006
Same author

If it looks like a cow and moos like a cow....

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2001
Same author

Alberta's Bill 11.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2001
Same journal

The Prognostic Significance of Advanced Lung Cancer Inflammation Index in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease Using Noninvasive Ventilatory Support.

Canadian respiratory journal·2026
Same journal

Effectiveness of Individualized Nursing in Perioperative Management of Patients With Obstructive Sleep Apnea: A Retrospective Cohort Study.

Canadian respiratory journal·2026
Same journal

Preliminary Study on the Effect of Bronchial Epithelial Cell-Released Autophagosome (BA)-Induced Neutrophils on Bronchial Epithelial Cells.

Canadian respiratory journal·2026
Same journal

Integrated Mindfulness and Cardiopulmonary Rehabilitation Improves Cardiopulmonary Performance and Psychological Stress in Pulmonary Arterial Hypertension.

Canadian respiratory journal·2026
Same journal

Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE-Specific Risk Profiling in Highland Populations.

Canadian respiratory journal·2026
Same journal

Cortex Mori Radicis Mitigates Inflammation and Fibrosis in Pulmonary Fibrosis Through PI3K/AKT Pathway Suppression.

Canadian respiratory journal·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Amiodarone pulmonary toxicity.

N Wolkove1, M Baltzan

  • 1Mount Sinai Hospital Centre, McGill University, Montreal, Canada. norluco@yahoo.com

Canadian Respiratory Journal
|April 29, 2009
PubMed
Summary
This summary is machine-generated.

Amiodarone pulmonary toxicity is a serious risk, even at lower doses. Early detection and treatment with amiodarone withdrawal and corticosteroids improve patient outcomes.

More Related Videos

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Amiodarone is a widely prescribed antiarrhythmic medication.
  • It is an iodine-containing compound that can accumulate in organs like the lungs.
  • Amiodarone pulmonary toxicity is a significant and potentially severe adverse event.

Purpose of the Study:

  • To highlight the risks and clinical manifestations of amiodarone pulmonary toxicity.
  • To emphasize the importance of clinician vigilance for this adverse effect.
  • To outline diagnostic and management strategies for amiodarone-induced lung injury.

Main Methods:

  • Review of clinical literature on amiodarone adverse events.
  • Description of typical and atypical presentations of pulmonary toxicity.
  • Discussion of diagnostic imaging findings (chest x-ray, HRCT).

Main Results:

  • Amiodarone pulmonary toxicity can occur at any dose, though lower doses may reduce incidence.
  • Clinical presentation includes acute/subacute pneumonitis with diffuse infiltrates, or localized forms like pleural disease or nodules.
  • Early diagnosis leads to a good prognosis.

Conclusions:

  • Clinicians must remain vigilant for amiodarone pulmonary toxicity, regardless of dosage.
  • Prompt diagnosis and management, including amiodarone withdrawal and corticosteroid therapy, are crucial for favorable outcomes.
  • Adherence to monitoring guidelines for both pulmonary and extrapulmonary adverse effects is essential.